… This review summarizes the current knowledge of EGFR TK domain mutations and the role
… importance of EGFR mutation status in the selection of patients for EGFR TKI therapy. EGFR …

… TKI-treated tumors as a form of acquired resistance (see section ‘Acquired EGFR mutations
in lung adenocarcinomas after EGFR receptor inhibitor treatment‘), primary resistance due to …

… With the advent of targeted therapy based on EGFR mutations in lung adenocarcinomas,
it is evident that the histologic subtype of NSCLC should be explicitly reported. …

… in lung adenocarcinoma—EGFR and KRAS mutations—that already have known biologic
and therapeutic relevance. Both mutations are oncogenic and importantly, EGFR mutations …

… for treatment with EGFR TK inhibitors against advanced lung adenocarcinomas, which often
… lung adenocarcinomas to the brain for EGFR mutations and compared the mutation status in …

… with stage IV lung adenocarcinomas, EGFR and KRAS mutations would identify patients
with … with advanced lung adenocarcinomas and known EGFR and KRAS mutation status. We …

… of EGFR mutations in East Asians with lung adenocarcinomas may … of pulmonary
adenocarcinoma. Our results did not show a correlation between the presence of an EGFR mutation …

… cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an
… of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. …

… EGFR mutation analyses in 3,071 consecutive lung cancer patients treated at the Guangdong
Lung Cancer … with small cell lung cancer, did not feature adenocarcinoma in any lesion, …

… In conclusion, lung adenocarcinoma with EGFR mutations is a distinct biological subset as
… rate to EGFR TKIs. Amplification of EGFR in NSCLC with EGFR mutation is common and, at …